MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Venture Capital: Risk Capital_Angel, Venture, Sovereign Wealth Investor Companies & Organizations
*Portfolio Companies: Sightline
CVRx Inc. (NASDAQ: CVRX)
Organization & Developments: CVRx
Parents
CVRx Inc. (NASDAQ: CVRX)
Children
*BAROSTIM NEO SYSTEM
*CVRx has a strong intellectual property foundation, which will protect the unique BAT technology.
*CVRx is developing proprietary technology for the treatment of high blood pressure and heart failure
*CVRx is focused on the development and commercialization of the Barostim™ System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of heart failure.
*CVRx reports positive four-year results for its anti-blood pressure device
*Hypertension
*Makes an implantable device to treat high blood pressure
*The Rheos System uses CVRx patented Baroreflex Activation Therapy® (BAT®) technology to trigger the body's own natural blood flow regulation system to treat high blood pressure and heart failure.
*This new device is called the Rheos® System.
*This product is currently under clinical evaluation in the United States for the treatment of high blood pressure and heart failure. The Rheos System is CE Marked and approved for sale for hypertension patients in Europe.
2013: The company has now reeled in more than $250 million since launching in 2001 (2013)
2021: CVRx_Fierce 15
2022: CVRx: Barostim Accelerating, Upside Targets Forming (Technical Analysis)_ seekingalpha.com
2022: CVRx’s Barostim Neo is a heart failure neuromodulation device.
2023: CVRx: Recent Good News Seems Fully Priced In Now_ seekingalpha.com
2024: CVRx announces new CPT® Category I codes for Barostim
Jumps
*Key People: CVRx
Finance & Acquisition: CVRx